Bruker CellScape Precise Spatial Proteomics Platform

Bruker has announced a new technology for its CellScape Precise Spatial Proteomics platform for highly multiplexed immunofluorescence. Launched in 2022, the CellScape platform captures the entire continuum of protein expression in a biological sample — from least to most abundant — while capturing fine morphological details. The platform uses directly-labeled primary antibodies, enabling researchers to build assays by combining panels and/or individual markers, even after the conclusion of an experimental run.

This week the company said it has advanced the CellScape chemistry with EpicIF (Enhanced photobleaching in cyclic immunofluorescence), which expands the range of compatible commercially available fluorophore-conjugated antibodies by nearly 10-fold, simplifies assay development, and increases throughput by up to twofold. EpicIF enhances photobleaching efficacy combining a proprietary reagent with visible light to gently erase fluorescence signal from nearly any fluorophore and, like the prior version, the epitopes are preserved while maintaining tissue integrity.

EpicIF is supported by the concurrent release of a new version of the software called CellScape Navigator, which introduces a more intuitive user interface and easy experiment setup. Both EpicIF and CellScape Navigator will be available as upgrades to current CellScape instruments, Bruker said.